RAFAEL HOLDINGS, INC. Cost of Revenue
RAFAEL HOLDINGS, INC. (RFL) reported Cost of Revenue of $38.00 thousand for the 3-month period ending 2025-01-31, per its 10-Q filed 2025-03-14.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2025-03-14
- RAFAEL HOLDINGS, INC. cost of revenue for the quarter ending 2025-01-31 was $38.00K.
- RAFAEL HOLDINGS, INC. cost of revenue for the quarter ending 2024-10-31 was $37.00K.
- RAFAEL HOLDINGS, INC. cost of revenue for the quarter ending 2024-07-31 was $69.00K.
- RAFAEL HOLDINGS, INC. cost of revenue for the quarter ending 2024-04-30 was $85.00K.
- RAFAEL HOLDINGS, INC. cost of revenue for fiscal 2024 was $154.00K.
- RAFAEL HOLDINGS, INC. cost of revenue for fiscal 2022 was $3.50M, a 10.41% increase from fiscal 2021.
- RAFAEL HOLDINGS, INC. cost of revenue for fiscal 2021 was $3.17M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-01-31 | $38.00K 10-Q · filed 2025-03-14 | $75.00K 10-Q · filed 2025-03-14 | $144.00K derived: sum of 3 quarters · filed 2025-03-14 | $229.00K derived: sum of 4 quarters · filed 2025-03-14 |
| 2024-10-31 | $37.00K 10-Q · filed 2024-12-11 | $106.00K derived: sum of 2 quarters · filed 2024-12-20 | $191.00K derived: sum of 3 quarters · filed 2024-12-20 | |
| 2024-07-31 | $69.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $154.00K derived: sum of 2 quarters · filed 2024-12-20 | $154.00K 10-K/A · filed 2024-12-20 | |
| 2024-04-30 | $85.00K 10-Q · filed 2024-06-14 | $85.00K 10-Q · filed 2024-06-14 | ||
| 2023-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | $0.00 derived: sum of 2 quarters · filed 2023-06-13 | $249.00K 10-Q · filed 2023-06-13 | $1.08M derived: sum of 4 quarters · filed 2023-06-13 |
| 2023-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-14 | $249.00K 10-Q · filed 2023-03-14 | $1.08M derived: sum of 3 quarters · filed 2023-03-14 | $1.88M derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-10-31 | $249.00K 10-Q · filed 2022-12-13 | $1.08M derived: sum of 2 quarters · filed 2022-12-13 | $1.88M derived: sum of 3 quarters · filed 2023-06-13 | $2.91M derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-07-31 | $829.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $1.63M derived: sum of 2 quarters · filed 2023-06-13 | $2.66M derived: sum of 3 quarters · filed 2023-06-13 | $3.50M 10-K · filed 2022-10-31 |
| 2022-04-30 | $799.00K 10-Q · filed 2023-06-13 | $1.83M derived: sum of 2 quarters · filed 2023-06-13 | $2.67M 10-Q · filed 2023-06-13 | |
| 2022-01-31 | $1.04M 10-Q · filed 2023-03-14 | $1.87M 10-Q · filed 2023-03-14 | ||
| 2021-10-31 | $835.00K 10-Q · filed 2022-12-13 | |||
| 2021-07-31 | $3.17M 10-K · filed 2022-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |